Led by $540m venture financing of Noom, total medical devices industry cross border venture financing deals worth $2.5bn were announced in North America in Q2 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 253.6% over the previous quarter and a rise of 225.8% when compared with the last four-quarter average of $776.67m.
North America held a 53.83% share of the global medical devices industry cross border venture financing deal value that totalled $4.7bn in Q2 2021. With a 53.40% share and deals worth $2.51bn, the US was the top country in North America’s cross border venture financing deal value across medical devices industry.
In terms of deal activity, North America recorded 41 cross border deals during Q2 2021, marking an increase of 32.26% over the previous quarter and a rise of 59.22% over the last four-quarter average. The US recorded 39 deals during the month.
North America medical devices industry cross border venture financing deals in Q2 2021: Top deals
The top five cross border venture financing deals accounted for 54.3% of the overall value during Q2 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $1.37bn, against the overall value of $2.5bn recorded for the quarter.
The top five medical devices cross border deals of Q2 2021 tracked by GlobalData were:
1) Novo Holdings, Oak HC/FT Partners, RRE Ventures, Samsung Ventures Investment, Sequoia Capital Operations, Silver Lake Management and Temasek Holdings (Private)’s $540m venture financing of Noom
2) The $276m venture financing of Element Biosciences by Counterpoint Global, Janus Henderson Investors, Logos Global Management, Meritech Capital Partners and T Rowe Price Associates
3) B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus’ $255m venture financing of InSilico Medicine
4) The $150m venture financing of EDDA Technology by 3W Partners, Orbimed Advisors and SoftBank Vision Fund II
5) Baillie Gifford, Fidelity Management & Research and Koch Disruptive Technologies’ venture financing of Shine Medical Technologies for $150m.